Phaseline

Targets › CYSLTR1

CYSLTR1 (Cysteinyl leukotriene receptor 1): drug programs, companies and trials

10 programs from 10 companies in 10 trials: 4 Phase 2, 2 Phase 3, 2 Phase 4, 2 Phase 1; Other, Cardiovascular, Immunology; next expected readout Dec 2026.

Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. (UniProt, Q9Y271)

Open in Phaseline: the race on CYSLTR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Colorado, DenverMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 4AlbuminuriaFeb 2027
House Ear InstituteMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 4Meniere Disease–
Shanghai Zhongshan HospitalMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 3Myocardial Infarction (MI)Feb 2027
Sherief Abd-ElsalamMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 3Rheumatoid ArthritisOct 2027
MediciNovaMN-001 (tipelukast)
Cysteinyl leukotriene receptor antagonist
CYSLTR1Phase 2Diabetes Mellitus, Type 2Dec 2026
Phramongkutklao College of Medicine and HospitalMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 2DengueJan 2027
October 6 UniversityMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 2Acute Myocardial Infarction (AMI)May 2027
Pakistan Institute of Medical SciencesMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 2Acute Bronchiolitis–
Duke Universitymontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 1Bronchopulmonary Dysplasia (BPD)Jun 2027
Baylor College of MedicineMontelukast
Cysteinyl leukotriene receptor 1 antagonist
CYSLTR1Phase 1Gulf War SyndromeApr 2028

Conditions

Dengue (1) Myocardial Infarction (MI) (1) Diabetes Mellitus, Type 2 (1) Acute Myocardial Infarction (AMI) (1) Albuminuria (1) Acute Bronchiolitis (1) Meniere Disease (1) Rheumatoid Arthritis (1) Gulf War Syndrome (1) Bronchopulmonary Dysplasia (BPD) (1)

Modalities

small molecule (10)

Companies

Phramongkutklao College of Medicine and Hospital (1) Shanghai Zhongshan Hospital (1) MediciNova (1) October 6 University (1) University of Colorado, Denver (1) Pakistan Institute of Medical Sciences (1) House Ear Institute (1) Sherief Abd-Elsalam (1) Baylor College of Medicine (1) Duke University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.